Charles River Laboratories International (NYSE:CRL) Upgraded at UBS Group

UBS Group upgraded shares of Charles River Laboratories International (NYSE:CRL) to a strong-buy rating in a research report released on Wednesday morning,Zacks reports.

A number of other research analysts have also recently issued reports on CRL. Morgan Stanley raised their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Royal Bank Of Canada boosted their target price on Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Mizuho increased their target price on Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a report on Friday, September 25th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $300.11.

Charles River Laboratories International Stock Up 1.2%

Shares of CRL opened at $290.32 on Wednesday. The firm has a market cap of $13.86 billion, a P/E ratio of -59.86, a P/E/G ratio of 2.67 and a beta of 1.40. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $303.30. The stock has a 50 day simple moving average of $277.46 and a two-hundred day simple moving average of $217.53. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period in the previous year, the business posted $3.12 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts forecast that Charles River Laboratories International will post 11.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CAO Michael Knell sold 6,645 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $260.38, for a total value of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shannon Parisotto sold 5,046 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. This represents a 51.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 90,990 shares of company stock worth $25,731,388. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its position in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after buying an additional 210,260 shares during the period. Bank of America Corp DE lifted its position in Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after acquiring an additional 54,500 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Charles River Laboratories International by 8.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company’s stock worth $166,813,000 after acquiring an additional 66,803 shares in the last quarter. Amundi boosted its stake in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in Charles River Laboratories International by 23.0% in the fourth quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company’s stock worth $102,058,000 after purchasing an additional 95,619 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.